Related Interviews

Slowing of Clinic Trial Data Hampers Early-Stage Biotechs
March 18, 2022
Nierengarten, David

Low Cost of Capital Sets Stage for Uptick in Biotech M&A
March 18, 2021
Nierengarten, David

M&A Starting to Pick Up as Valuations Come Down
October 04, 2019
Yang, Difei

A Big Year Ahead for Gene and Cell Therapy Companies
March 22, 2019
Prasad, Raju

Major Pharmas Becoming Increasingly Comfortable with Gene Therapy
March 22, 2019
Zhong, Yun

The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Singh, Hartaj

CRISPR and NASH Will Be Particularly Interesting and Exciting in 2019
March 15, 2019
Seedhouse, Steven

Relatively Healthy Valuations for Development-Stage Companies
October 02, 2018
Nierengarten, David

Data Consistency is Important When Investing in Gene Therapy
March 21, 2018
Chattopadhyay, Debjit

Gene Editing Companies Have Long-Term Potential to Be M&A Targets
March 16, 2018
Amusa, Gbola

Downturn in Biotech Creates Opportunities for Investors to Realize Superior Gains
April 21, 2017
Markey, Keith A.

Biotech Space on the Cusp of Seismic Changes
April 21, 2017
Chattopadhyay, Debjit

Applying Bottom-Up Fundamental Research in the Large-Cap Space
February 24, 2017
Fitzpatrick, Owen

Opportunities in Regenerative Medicine, Cancer Immunotherapy Markets for Value Investors
July 06, 2015

Biotech Space Concentrates on Gene Therapy, CAR T-Cell Technology Side
July 23, 2014

Targeted Genetic and Cell Therapies Stand Out in Biotechnology
April 01, 2014

Lon L.e. Vining - Angoss Software Corporation (anc:tsx.v)
June 04, 2007

Todd Ahlsten - Parnassus Investments
February 17, 2003